The incidence of erectile dysfunction increases with diabetes, hypertension, hypercholesterolaemia, cardiovascular disease and renal failure. All these conditions are associated with endothelial dysfunction. This review addresses the pathophysiology of erectile dysfunction with a special focus on new insights into nitric oxide (NO)-mediated pathways, oxidative stress and parallels to endothelial dysfunction. NO appears to be the key mediator promoting endothelium-derived vasodilation and penile erection. The possibility is discussed that elevated plasma concentrations of asymmetrical dimethylarginine (ADMA), an endogenous NO synthase inhibitor, may provide an additional pathomechanism for various forms of erectile dysfunction associated with cardiovascular risk factors and disease. Likewise, the role of endotheliumderived factors mediating NO-independent pathways is evaluated.
Introduction
In western countries, at least one in ten men is affected by erectile dysfunction, which is de ned as the inability to maintain an erection suf cient to permit satisfactory sexual intercourse. 1 It has been estimated that about 30 million men in the USA or half a million men in the UK have partial or complete erectile dysfunction. 1 ,2 Based on data from a predominantly white population, the estimated worldwide incidence of erectile dysfunction will increase from roughly 152 million men in 1995 to 322 million men by the year 2025. 3 However, due to social, ethnic and cultural factors leading to differences in the perception and reporting of erectile dysfunction, precise estimates of the worldwide incidence and prevalence of erectile dysfunction are dif cult to obtain.
Erectile dysfunction is commonly classi ed as organic, psychogenic or mixed organic and psychogenic, with organic erectile dysfunction being the most common form. 1 Organic erectile dysfunction, if not traumatic, is usually caused by abnormal function and responsiveness of the penile vasculature attributed to aging 4 -6 or underlying diseases. 7 ,8 Moreover, there is accumulating evidence that erectile dysfunction may be just another manifestation of cardiovascular disease. 9 ,1 0 In addition, a considerable number of patients may suffer from drug-induced erectile dysfunction. 1 1 ,1 2 The risk of erectile dysfunction increases with diabetes, 1 3 -1 6 hypercholesterolaemia, 1 5 ,1 7 ,1 8 hypertension, 6 ,1 5 atherosclerosis 1 2 ,1 5 and renal failure. 1 9 -2 1 All of these dis-eases and conditions are also known to be associated with endothelial dysfunction. 2 2 - 3 8 Dysfunction of the endothelium may be interpreted as the ruin of the homeostasis between constricting and relaxing factors. 3 9 The pathogenesis of endothelial dysfunction is as multi-factorial as clinical interventions are. 4 0 ,4 1 Nevertheless, one mediator of smooth muscle relaxation seems to be a key gure in endothelial function and dysfunction: endothelium-derived nitric oxide (NO). 4 2 , 4 3 This provides a strong link to the physiology and pathophysiology of penile erection where NO-mediated relaxation of smooth muscles also plays a decisive role. 4 4 Impaired NO formation may therefore be considered a key pathomechanism in both endothelial 4 5 ,4 6 and erectile dysfunction. 4 7 ,4 8 It has to be emphasized that the involvement of the endothelium in the regulation of penile tone is rather complex and that important contributions may come from NO-independent pathways. Prostaglandin, 4 9 ,5 0 endothelin, 5 1 angiotensin, 5 2 bradykinin 5 2 or endothelium-derived hyperpolarizing factor-mediated 5 3 pathways may provide additional mechanisms for the regulation of penile tone.
In the following review, we address the pathophysiology of erectile dysfunction with a special focus on new insights into NO-mediated pathways, oxidative stress and parallels to endothelial dysfunction. Based on these data an outlook is given on potential targets for restoring impaired endothelium-dependent relaxation in penile erection.
NO-mediated pathways and mechanisms of impaired NO synthesis NO, synthesized from l-arginine (Figure 1 ), is the key mediator of endothelium-dependent smooth muscle relaxation, 5 4 -5 6 and likewise it is the key mediator of penile erection 4 7 ,5 7 ,5 8 (a simpli ed summary of the most important NO is a free radical and easily reacts with other free radicals such as superoxide anions (O -2 ) to form peroxynitrite (ONOO -). l-Arginine, the substrate for NOS, is transported into the cell via speci c transporters such as y + . Inside the cell NOS competes with arginases for l-arginine. NOS expression is regulated by various endogenous and exogenous factors. Synthesis of NO is dependent on availability of the substrate l-arginine, calmodulin/Ca 2 + and additional co-factors such as tetrahydrobiopterin (TBH), nicotinamide adenine dinucleotide phosphate (NADPH), avin-adenine-mononucleotide (FMN) and avin-adenine-dinucleotide (FAD). NOS can be inhibited by endogenous compounds such as asymmetrical dimethylarginine (ADMA). ADMA is degraded by dimethylarginine dimethylaminohydrolase (DDAH).
pathways governing smooth muscle relaxation in penile erection is given in Figure 2 ). NO can be synthesized and released from non-adrenergic, non-cholinergic nerve endings by speci c neuronal synthases (nNOS) and from the Figure 2 A simpli ed scheme of neuronal and endothelium-mediated relaxation and contraction of penile smooth muscle. (a 1 , a 1receptor; a2, a2-receptor; M3, M3-receptor; ETA, endothelin receptor type A; ETB, endothelin receptor type B; G, G-protein; Gq, Gqprotein; G s , G s -protein; NO, nitric oxide; eNOS, endothelial NO synthase; nNOS, neuronal NO synthase; PDE, phosphodiesterase; PGHS, prostaglandin H 2 synthase; PGE-S, prostaglandin E 2 synthase; PGF-S, prostaglandin F 2 a synthase; EP, EP prostaglandin receptor; FP, FP prostaglandin receptor; IP3, inositol-1,4,5-trisphosphate; AA, arachidonic acid; PLC, phospholipase C; PGE2, prostaglandin E 2 ; PGF 2 a , prostaglandin F 2 .) Vascular Medicine 2002; 7: 213-225 endothelium by endothelial NO synthases (eNOS). 4 4 As detailed below, NOS may be up/down-regulated, inhibited or activated. Upon sexual stimulation NO is released directly from nerve endings or from endothelial cells stimu-lated by acetylcholine released from cholinergic nerve endings. 7 Even though involvement of both endothelial and neuronal NO synthesis in penile erection has been proposed from early on, 4 7 the relative importance of both pathways has been subject to considerable debate. Inhibition of neuronal NO synthesis attenuated erectile responses. 5 9 But surprisingly, mice lacking nNOS showed no overt signs of erectile dysfunction. 6 0 ,6 1 This has been attributed to splicing variants of nNOS or to additional expression of a penisspeci c NOS (PnNOS) in nNOS knock-out mice. 6 2 Erectile function was also found to be preserved in mice lacking eNOS. 6 3 However, intracavernosal pressure during erection was signi cantly decreased in eNOS-de cient mice and, over all, NO synthase activity was only 60% of the activity observed in wild-type mice. Thus, it is very likely that physiologic penile erection is mediated by both nNOS and eNOS. Even though inducible NO synthases have been described in the penis, too, their role in penile erection or erectile dysfunction has not been de ned yet. 6 4 NO activates a soluble guanylyl cyclase that forms cyclic guanosine monophosphate (cGMP). 6 5 Reports of erectile dysfunction in cGMP-dependent kinase-I (cGKI)-de cient mice suggest that cGMP is indeed the principal second messenger in erectile dysfunction. 6 6 These ndings are strongly supported by data on the clinical ef cacy of the phosphodiesterase type 5 inhibitor sildena l, which prevents the degradation of cGMP. 6 7 Furthermore, the study in cGKI-de cient mice demonstrated that cAMP-mediated pathways cannot compensate de cient cGMP-dependent signalling in vivo. 6 6 In humans the situation might be different, however. Prostaglandin E 1 and its derivative alprostadil, which induce relaxation predominantly via the cAMP pathway, were found to be highly effective in the treatment of erectile dysfunction. 5 0 , 6 8 cGKI appears to regulate myosin light chain phosphatases causing subsequent relaxation of smooth muscle. 6 9 These ndings open an unexpected link to noradrenergic and Rho-kinase mediated contraction of penile musculature that counteract the NO-mediated relaxation. 7 0 Rho-kinase phosphorylates (and thus inhibits) smooth muscle myosin phosphatases. This in turn results in sensitization of myolaments to Ca 2 + and enhances contraction. The Rho-kinase antagonist Y-27632 stimulates penile erection in the rat independently of the NO pathway. 7 1 Thus, antagonism of Rho-kinases provides an interesting new target for pharmacologic therapies that completely circumvent the NO pathway.
The relative importance of other pathways beyond cGMP which lead to a reduced Ca 2 + in ux and subsequent relaxation of the penile smooth muscle is yet unknown.
Whatever the principal molecular mechanisms may be, the nal result of relaxation of small arteries and arterioles supplying erectile tissues and the relaxation of trabecular smooth muscles is rapid lling and expansion of the erectile tissue. 7 The haemodynamic changes leading to an erection are reversed during detumescence; i.e. the return to the normal accid state. 7 2 During a transition phase with increased sympathetic activity causing contraction of the trabecular smooth muscle and increasing the tone of the helicine arteries, arterial ow resumes at a low level. The following detumescense is characterized by a decline of intracavernous pressure, reopening of the venous out ow and a decrease of arterial ow to its prestimulation level. Availability of the substrate l-arginine Several principal pathomechanisms may account for reduced availability of NO in both endothelial and erectile dysfunction. NO synthesis is dependent on availability of the substrate l-arginine, calmodulin/Ca 2 + and additional cofactors like tetrahydrobiopterin, nicotinamide adenine dinucleotide phosphate (NADPH), avin-adenine-mononucleotide (FMN) and avin-adenine-dinucleotide (FAD). 7 3 For NO synthesis the substrate l-arginine is transported into mammalian cells by at least four different carrier systems (y + , y + L, b 0 ,+ and B 0 ,+ ). 7 4 The regulation of these carriers is complex and not yet fully understood, but it is of interest to note that the l-arginine transport via the y + carrier can be inhibited by endogenous l-arginine analogues such as asymmetrical dimethylarginine (ADMA). 7 5 As detailed below, elevated plasma ADMA concentrations are found in many conditions associated with erectile dysfunction (see Table 2 ). l-Arginine transport may also be inhibited non-competitively by uraemic levels of urea. 7 6 In the cell, NO synthases have to compete with other enzymes like arginases for the substrate l-arginine. Inhibition of arginase activity by 2(S)-amino-6-boronohexanoic acid (ABH) has been shown to cause signi cant enhancement of non-adrenergic, non-cholinergic nerve-mediated relaxation of penile corpus cavernosum smooth muscle, suggesting that arginase inhibition sustains l-arginine concentrations for NO. 7 7 Moreover, a recent study demonstrated that diabetic corpus cavernosum from humans with erectile dysfunction had higher levels of arginase II protein, gene expression and enzyme activity than normal human cavernosal tissue. 7 8 The impaired ability of diabetic tissue to synthesize NO was reversed by the selective inhibition of arginase activity by ABH. Increased expression of arginase II in diabetic cavernosal tissue may therefore contribute to the erectile dysfunction associated with diabetes.
NOS expression and a link to the eicosanoid pathway
Expression of NOS may be inducible (iNOS) or constitutive. 7 9 Under physiological conditions eNOS and nNOS are constitutively expressed in the endothelium and penile nerve endings, respectively. 8 0 -8 2 But this expression is not entirely constitutive. Expression of eNOS and nNOS is subject to rather complex regulatory mechanisms (for further details please refer to comprehensive reviews 7 3 ,8 3 ). Selected factors affecting the expression of eNOS are summarized in Table 1 . Data on the role of most of these factors in erectile dysfunction are rather limited and sometimes conicting, however. Reduced androgen concentrations, as found in elderly individuals, may result in impaired expression of penile NO synthases (eNOS and nNOS). 9 6 On the other hand, an aging-related increase in expression of iNOS has been described. 1 1 0 And, conversely, in rabbit cavernosal tissue, eNOS appeared to be up-regulated with increasing age. 1 0 2 However, NO synthesis was found to be impaired in elderly rabbits. Likewise, in animal models of uraemia, nNOS expression and protein levels were found to be elevated while NO production was decreased. 1 0 0 ,1 0 1 The same inves- 8 4 Hypertension 8 5 Low salt intake 8 6 High salt intake 8 7 Low concentration of oxidized High concentration of oxidized LDL 8 8 LDL 8 9 HMG-CoA-reductase Glucocorticoids 9 1 inhibitors 9 0 Angiotensin II 8 6 Tumour necrosis factor-a 9 2 Increase in cGMP 9 3 Increase in cAMP 9 4 High glucose 9 5 Low androgens 9 6 Calcium channel blockers 9 7 ,9 8 PGE 1 9 9 Uraemia 1 0 0,10 1 Old age 1 0 2 Lysophosphatidylcholine 1 0 3 Hyperthyroidism 1 0 4 b1-adrenoceptor blocker 1 0 5 Exercise training: divergent data for up-regulation 1 0 6 and unchanged expression 1 0 7 Hypoxia: divergent data for up-1 0 8 and down-regulation 1 0 9 tigators found eNOS mRNA content unchanged but eNOS protein levels raised. 1 0 1 Also of interest may be the inhibitory effects of atherogenic lipids/lipoproteins on eNOS expression 8 9 and endothelial function as a whole (reviewed by Adams et al, 2000 1 1 1 ). Among their pleiotropic effects on endothelial function, HMG-CoA-reductase inhibitors were found to increase expression of eNOS. 9 0 NO activates prostaglandin synthesis. 1 1 2 ,1 1 3 Constitutive prostaglandin H2 synthase (PGHS)-1 is expressed in tandem with prostacyclin synthase in endothelial cells. 1 1 4 The resulting prostacyclin together with NO released after nNOS and eNOS stimulation ensures relaxation of smooth muscle cells. Under pathophysiologic conditions the situation changes. In in ammation, iNOS is induced by cytokines in the vessel wall. iNOS is co-expressed with the inducible form of PGHS, i.e. PGHS-2. 1 1 5 ,1 1 6 Interestingly, PGHS-2 and prostacyclin synthase were not found to be co-localized in endothelial cells. 1 1 4 Moreover, after IL1b stimulation prostacyclin synthase was inactivated. 1 1 7 Hence, a shift from vasodilatory prostaglandins and prostacyclin to vasoconstrictory eicosanoids is likely. Expression of eNOS is down-regulated after induction of in ammatory cytokines. 1 1 8 ,1 1 9 Even though additional NO is provided from iNOS (probably to combat vasoconstrictory eicosanoids), NO from nNOS and eNOS after neuronal stimulation may no longer suf ce for smooth muscle relaxation. Erectile dysfunction would be the consequence. A chronic in ammatory process such as atherosclerosis 1 2 0 may be suf cient to induce this scenario.
Oxidative stress and impaired NO availability
With accumulating evidence for oxidative stress playing a causative role in atherosclerosis 1 2 1 and endothelial dysfunction, 1 1 9 ,1 2 1 ,1 2 2 suspicions are rising that oxidative stress might also contribute to erectile dysfunction. 1 2 3 The precise Vascular Medicine 2002; 7: [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] contribution of oxidative stress to erectile dysfunction has not been evaluated in detail yet, but some mechanisms described for endothelial dysfunction are very likely to have parallels in erectile dysfunction. By reacting with NO itself or by interfering with NO-mediated pathways, highly reactive oxygen species (ROS) could possibly contribute to erectile dysfunction. 1 2 4 These mechanisms might deserve some attention since it could be demonstrated that infusion of the antioxidant ascorbic acid restored vascular responses to acetylcholine in patients with endothelial dysfunction. 1 2 2 ,1 2 5
Some authors have proposed that nascent NO can be quenched immediately after its synthesis. This 'uncoupling phenomenon' was suggested for nNOS and eNOS unsaturated with the substrate l-arginine or co-factors. 1 2 6 ,1 2 7 Nitric oxide synthases depend on tetrahydrobiopterin as a co-factor. 7 3 Endothelial dysfunction associated with tetrahydrobiopterin depletion could be reversed by tetrahydrobiopterin supplementation. 1 2 8 -1 3 0 In the rabbit corpus cavernosum, tetrahydrobiopterin increased NOS activity by 30%. 1 3 1 Ascorbic acid was able to potentiate NO synthesis via chemical stabilization of tetrahydrobiopterin. 1 3 2 Depletion of tetrahydrobiopterin has been associated with states of increased free radical burden (e.g. oxidative stress). 1 2 9 Responsible for the NO quench are ROS-like superoxide anions (O -2 ). 1 3 3 The reaction between NO and O -2 is likely since the two radicals combine extremely fast to the 'ugly' peroxynitrite (ONOO -). 1 3 4 Peroxynitrite reacts with proteins by nitrating tyrosyl residues. This leads to enzyme inactivation (e.g. inactivation of prostacyclin synthase or superoxide dismutase). 1 3 5 ,1 3 6 Diminished bioavailability of NO has been implicated with atherosclerosis and cardiovascular disease. One independent risk factor of atherosclerosis and cardiovascular disease is hyperhomocyst(e)inaemia. 1 3 7 ,1 3 8 Homocysteine also reduces endothelium-dependent relaxation of the corpus cavernosum, probably due to generation of O -2 resulting in ONOOformation. 1 3 9 Although ONOOrelaxes cavernosal smooth muscle cells via cGMP formation, it is less potent than the NO from which it was formed and may therefore contribute to erectile dysfunction. 1 4 0 Superoxide anion is an intermediate product of incomplete oxygen reduction by cytochrome C oxidase from the respiratory chain. Several other sources of O -2 , such as NAD(P)H oxidases or xanthin oxidase, and their role in cardiovascular biology have recently been reviewed. 1 4 1 ,1 4 2 Aerobic life has evoked an enzymatic defence by superoxide dismutases (SOD). The three isoforms MnSOD, CuZnSOD and extracellular (ec)SOD are found in the mitochondria, cytosol and extracellular uids, respectively. 1 4 3 The ecSOD is located between the endothelium and vascular smooth muscle cells and prevents degradation of NO by scavenging O -2 . 1 4 4 ,1 4 5 The expression and secretion of ecSOD is up-regulated after vasoconstriction with vasopressin, endothelin-1 or angiotensin II. 1 4 6 ,1 4 7 On the other hand, endothelial NO stimulates ecSOD, too. 1 0 6 The effects probably show the key role of ecSOD in maintaining homeostasis of vascular tone. 1 4 5 In accordance, in young hypercholesterolaemic individuals, activity of ecSOD is high 1 4 8 while in patients with manifested endothelial dysfunction (i.e. coronary artery disease) ecSOD activity is diminished, probably due to a progressed pathophysiologic process. 1 4 8 It is not only hypercholesterolaemia that impairs endothelium-dependent relaxation in the corpus cav-ernosum. 1 4 9 Diabetes mellitus is also associated with impaired endothelium-mediated relaxation of penile smooth muscle. 1 5 0 In the rabbit, diabetes-related reduction of NOmediated relaxation of cavernosal tissue could be reversed by SOD. 1 5 1 ,1 5 2 Further studies have found that glycosylated human haemoglobin impaired smooth muscle relaxation. 1 5 3 This effect has been in part attributed to the generation of O -2 and extracellular inactivation of NO since the impairment of cavernosal smooth muscle relaxation related to glycosylated haemoglobin could be reversed by exogenous SOD.
Inhibition of NOS
As detailed above, the incidence of erectile dysfunction increases with atherosclerosis, 1 5 ,1 8 diabetes, 1 3 -1 5 hypertension, 6 ,1 5 hypercholesterolaemia 1 5 ,1 7 and renal failure. 1 9 -2 1 All of these conditions are associated with an altered endothelial NO production. In addition, impaired NO production has been proposed as the common link between vascular disease and erectile dysfunction. 9 Some conditions might be attributed to an altered NOS expression (see Table 1 ), but more and more studies suggest that impaired NOS function rather than NOS expression may be the cause of insufcient NO production. 1 0 1 This draws the attention to a long list of NO inhibitors commonly employed to study the NO-l-arginine pathway in erectile dysfunction. 5 7 ,1 5 4 ,1 5 5 Analogues of l-arginine such as N G -monomethyl-l-arginine (l-NMMA), N G -nitrol-arginine (l-NNA) and N G -nitro-l-arginine methyl ester (l-NAME) effectively inhibit the relaxation of cavernous tissue. 4 7 ,4 8 ,1 5 6 -1 5 8 The inhibitory effect is counteracted by exogenous l-arginine. 4 7 ,4 8 Their ef cacy in provoking erectile dysfunction under various in vitro and in vivo conditions highlights the potential importance of NOS inhibitors in erectile dysfunction. Yet, none of the NOS inhibitors preferentially studied in erectile dysfunction reaches physiologically relevant concentrations in vivo. 1 5 9 Surprisingly, one NOS inhibitor has received only little attention in erectile dysfunction so far: ADMA. Many conditions associated with erectile dysfunction are known to be associated with elevated plasma levels of ADMA 3 7 ,1 6 0 -1 6 8 (summarized in Table 2 ). ADMA is a selective, endogenous NOS-inhibitor, 1 6 4 formed by the hydrolysis of proteins containing methylated arginine residues. 1 7 6 ,1 7 7 Elevated ADMA plasma levels were rst described in patients with chronic renal failure by Vallance et al in 1992 1 6 4 and linked to impaired NO synthesis. Since then plasma ADMA levels were shown to be positively correlated with age, mean arterial pressure, glucose tolerance and extent of atherosclerosis. 1 6 2 ,1 6 3 ,1 6 9 ,1 7 0 In healthy subjects, the mean plasma ADMA concentration ranges from 0.5 to 1 mM. 1 6 4 ,1 7 1 In patients with cardiovascular risk factors, the plasma level is typically increased two fold. 3 8 Furthermore, in patients with clinical atherosclerotic disease or end-stage renal disease, plasma ADMA concentrations are even increased further, up to 3.5-fold and 10.4-fold, respectively. 3 7 ,1 6 4 ,1 6 6 ,1 6 7 ,1 6 9 It was shown that in diabetic patients with otherwise normal ADMA levels typical (western) high fat meals were associated with an acute 2.5-fold increase of plasma ADMA levels and profound endothelial dysfunction. 1 failure could be attributed at least in part to reduced renal excretion, the precise cause of elevated ADMA levels in other diseases has not been identi ed yet. One cause could be a reduced activity of dimethylarginine dimethylaminohydrolase (DDAH), which degrades ADMA. DDAH activity may be inhibited by elevated concentrations of homocysteine or cholesterol. 1 7 9 ,1 8 0 Several groups, including our own, could demonstrate that elevated plasma ADMA levels are associated with impaired endothelium-dependent vasodilation and reduced urinary nitrate excretion. 3 8 ,1 8 1 Intra-arterial infusion of ADMA (8 and 16 mmol/min) in healthy volunteers caused a signi cant, dose-dependent reduction in forearm blood ow. 1 8 2 Since this effect was attenuated by infusion of excess l-arginine it was attributed to impairment of NOS activity by ADMA. This nding strengthens the point that ADMA is not only a marker but also a cause of endothelial dysfunction. Similar results on vascular tone could be obtained in vitro from human cerebral arteries. 1 8 3 Rising ADMA concentrations from 1 mmol/l to 10 mmol/l were shown to cause moderate contractions of cerebral vessels in situ. 1 5 9 In cerebral tissues, the IC 5 0 value of ADMA for inhibition of NO production has been calculated to be between 1.5 and 2.3 mmol/l, 1 5 9 ,1 8 4 i.e. within the (patho-) physiological concentration range. Under pathological conditions ADMA reaches tissue concentrations likely to be suf cient to inhibit NO synthesis. 1 5 9 ,1 8 3 ,1 8 4 The parallels between cardiovascular risk factors, endothelial dysfunction, erectile dysfunction and elevated ADMA concentration are striking (Table 2) .
Since ADMA concentrations found in diabetes, hyperlipoproteinaemia, renal failure and cardiovascular disease are high enough to interfere with endothelial NO synthesis and to cause endothelial dysfunction, we hypothesize that elevated ADMA levels can also interfere with penile NO synthesis and smooth muscle function. Thus, ADMA may provide an additional pathomechanism for erectile dysfunction shared by many conditions associated with both endothelial and erectile dysfunction. In several clinical trials endothelial dysfunction associated with elevated ADMA levels was restored by supplementation of l-arginine. 3 2 ,1 8 5 ,1 8 6 In a rabbit model of chronic cavernosal ischaemia, impaired smooth muscle relaxation was found not to be related to the ability of erectile tissue to relax to NO. 1 8 7 Rather, it appeared to be related to an impaired NO production by the endothelium. In the same study, endothelium-dependent relaxation impaired by hypercholesterolaemia could be completely restored by l-arginine. In animals with chronic cavernosal ischaemia, l-arginine could only partially restore endothelium-dependent relaxation. This suggests that in chronic ischaemia further steps in the NO-mediated pathway may be involved. Results from clinical trials in patients with erectile dysfunction have been controversial. 1 8 8 ,1 8 9 Only patients with an initially reduced nitrate excretion (as a marker of impaired NO production) reported an improvement. 1 8 8 Today, l-arginine plays only a marginal role in the treatment of erectile dysfunction. Elevated ADMA concentrations offer a possible explanation for conicting data and may encourage a second look at l-arginine treatments in erectile dysfunction: l-arginine has been shown to restore NO synthesis impaired by methylated larginine analogues, 4 7 ,4 8 including ADMA. 1 6 4 ,1 9 0 Patients with elevated plasma ADMA levels and decreased NO pro- Table 2 Plasma ADMA concentrations and risk of erectile dysfunction in conditions associated with endothelial dysfunction.
Condition associated with
Plasma ADMA concentration Incidence of erectile endothelial dysfunction " 5 elevation versus control dysfunction " 5 elevated risk versus control Atherosclerosis 2 2 ,2 3 " 2.1-3.53 3 7 ,1 62 " 2.63 1 5 ,1 8 Correlates with extent of disease 1 6 9 Correlates with prognosis of disease 1 7 0 Hypertension 2 4 ,2 5
" 2.2-2.33 1 6 1, 16 3 " 1.4-1.63 6 ,1 5 Correlates with arterial pressure 1 6 2 Diabetes 2 6 ,2 7 " 2.33 1 7 1 " 1.7-4.63 1 3 -1 5 Correlates with index of blood glucose 1 6 2 Renal failure 2 8 ,2 9
" 2-10.43 1 6 4-16 7 50-82% of patients Correlates with prognosis of disease 1 7 2 affected 1 9 -2 1 Hypercholesterolaemia 2 6 ,3 0-32 " 2.23 1 6 8 " 1.6-1.83 1 5 ,1 7 Correlation not seen in all collectives with hypercholesterolaemia 1 6 2
Correlates with total cholesterol 1 7 Smoking 3 3 ,3 4 No data available " 1.4-2.53 1 5 ,1 73 -1 7 5 Old age 3 1 , 3 5,36 " Increases with age 1 6 2 Increasing with age (up to 103) 4 ,5 duction should be more likely than others to bene t from treatment with l-arginine. It has to be emphasized, however, that an association of a factor with a disease does not necessarily imply causality. 1 9 1 To pursue this issue we initiated a clinical trial to investigate the role of ADMA in erectile dysfunction.
NO-independent mechanisms involved in endothelial and erectile dysfunction

Prostaglandins
Eicosanoids are synthesized in the blood vessels as modulators of vascular tone by PGHS and subsequent conversion to prostaglandin (PG) E 2 , PGF 2 a , PGD 2 , prostacyclin (PGI 2 ) or thromboxane (TxB 2 ) by PGE synthase, PGF synthase, PGD synthase, PGI synthase, or thromboxane synthase, respectively (reviewed in 1 9 2 ,1 9 3 ). Both isoforms of PGHS, i.e. PGHS-1 and PGHS-2, are expressed in endothelial cells and smooth muscle cells constitutively or inducibly, respectively. 1 9 4 ,1 9 5 The regulation of expression in the vasculature has been discussed in detail elsewhere. 1 9 6 PGI synthase is predominantly located in the vascular endothelium and smooth muscle. 1 9 7 Rate-limiting for eicosanoid release is not only the expression of PGHS and PGI synthase but also the availability of the precursor arachidonic acid. Arachidonic acid is released from phospholipids by phospholipase A 2 , which is inducible by interleukins together with PGHS-2, PGE synthase and PGI synthase, leading to a vast amount of vasodilatory prostanoids in human endothelial cells in sepsis and in ammation. 1 9 8 -2 0 1 In addition, phospholipase A 2 may be activated by endothelin-1, which provides a crosslink to the endothelin-mediated effects discussed further below.
Human corpus cavernosum has the ability to synthesize all the eicosanoids mentioned above. 2 0 2 ,2 0 3 PGI 2 formed in the penile tissue dilates blood vessels and inhibits platelet adhesion and aggregation. 2 0 4 ,2 0 5 But only PGE 2 and its derivative PGE 1 were found to relax the corpus cavernosum and spongiosum. 2 0 6 The relaxant effects of PGE 2 and PGE 1 are likely to be mediated via activation of adenylyl cyclase Vascular Medicine 2002; 7: [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] and subsequent elevation of intracellular cAMP in the human corpus cavernosum. 2 0 7 This effect was mediated via stimulation of prostanoid receptors. The established clinical ef cacy of PGE 1 and its derivative alprostadil highlight the role of eicosanoids in penile function. 5 0 , 6 8 In diabetic men, PGE 1 receptors are down-regulated. 2 0 8 Moreover, in animal models of diabetes mellitus, prostacyclin formation is diminished. 2 0 9 ,2 1 0 Both mechanisms may contribute to an imbalance the penile eicosanoid homeostasis. The resulting vasoconstriction of penile blood vessels and contraction of corpus cavernosum provides a further pathomechanism to explain the high incidence of erectile dysfunction in diabetes mellitus.
Recent data suggest that upon stimulation by acetylcholine, endothelial cells in the penis do not only release vasodilatory NO but also vasoconstrictory prostanoids. 2 1 1 Under physiological conditions NO-mediated relaxation stimulated by acetylcholine outweighs the effects of constrictory eicosanoids, including prostanoids and thromboxane. But in conditions of impaired NO release, the co-release of vasoconstrictory eicosanoids may signi cantly impair acetylcholine-mediated relaxation.
These ndings may also be interesting in the light of data from in vitro studies, 1 8 7 suggesting that inhibition of constrictory eicosanoids by drugs such as indomethacin can improve the ability of cavernosal tissue to relax. However, the effectiveness of these drugs in erectile dysfunction has not yet been demonstrated in vivo.
Angiotensin and kinins
The angiotensin system and kinins may provide further mechanisms regulating both vascular and penile tone. Angiotensin-and bradykinin-receptors have been characterized both in the systemic vasculature and in erectile tissues. 2 12-216 Bradykinin was able to elicit dose-dependent relaxation of norepinephrine-induced tension in isolated corpus cavernosum strips, whereas angiotensin II caused dose-dependent contraction. 5 2 Furthermore, in dogs, intracavernosal angiotensin II terminated spontaneous erections while an intercavernosal angiotensin II antagonist increased intracavernosal blood pressure. In the stage of penile detu-mescence, a transient increase of the angiotensin II concentration in the corpus cavernosum was observed in healthy volunteers. 5 2 When compared with healthy volunteers, both local angiotensin II concentrations in the corpus cavernosum and systemic concentrations were elevated in patients with organic erectile dysfunction. 2 1 7 In addition to a possible systemic origin of angiotensin and kinins, there is emerging evidence that the endothelial and smooth muscle cells in the human corpus cavernosum form a local angiotensin II-producing paracrine system. In human volunteers the concentrations of angiotensin II in the corpus cavernosum were found to be higher than those in samples taken from the cubital vein in all stages of penile erection and detumescence. 5 2 ,2 1 7 Given the very short plasma halflife of angiotensin II, local production is the most likely source in this case. While inhibition of the angiotensin-converting enzyme decreases the concentration of angiotensin II by preventing the formation of angiotensin II from angiotensin I, inhibition of the angiotensin-converting enzyme increases the concentration of bradykinin by inhibiting its degradation. Thus, it has been suggested that inhibition of the angiotensin-converting enzyme might have some direct bene cial effects in erectile dysfunction since it increases the concentration of bradykinin and decreases the concentration of angiotensin II.
Endothelins
Endothelin-1, 2 and 3 are mainly known as peptides with potent vasoconstrictor activity. 2 1 8 ,2 1 9 Endothelin-1 is the primary endothelium-derived endothelin. Two types of endothelin receptors (ET A and ET B ) have been described. The vascular effects of endothelins and the corresponding second messenger pathways are complex and not yet fully understood. Endothelins act on the endothelium (mainly ET B ) and on smooth muscle (ET A and ET B ). Activation of ET A receptors predominantly causes contraction of vascular smooth muscle, whereas activation of ET B receptors on endothelial cells results in release of NO and prostacyclin and may mediate smooth muscle relaxation. In most vascular beds endothelin-1 causes an initial vasodilation followed by a vasoconstriction. It has been shown that ET A and ET B receptors can couple to overlapping sets of G-proteins. A common pathway is the subsequent activation of phospholipase C b which increases inositol-1,4,5-trisphosphate and nally results in elevation of Ca 2 + . 2 1 8 However, additional phospholipases and subsequent pathways are likely to be involved in endothelin-dependent signalling. 2 2 0
In addition it has been demonstrated that at physiological concentrations endothelin-1 may enhance the contractile effects of other mediators such as PGF 2 a or 5-hydroxytryptamine. 2 2 1 -2 2 3 Smooth muscle sensitization to Ca 2 + may be one possible mechanism. Two distinct pathways seem to be involved in these effects: 2 2 4 a Ca 2 + -sensitive protein kinase C (PKC)-mediated pathway not involving tyrosine phosphorylation or activation of mitogen-activated protein kinase (MAPK) and a Ca 2 + -insensitive PKC-mediated pathway involving tyrosine phosphorylation and activation of MAPK. 2 2 4 In summary, endothelin-1 may be an interesting target for mediating the net effect of vasoconstrictor substances.
Both endothelin and endothelin receptors type A and B have been identi ed in erectile tissues and in cultured endothelial cells from human corpus cavernosum. 5 1 Vascular Medicine 2002; 7: [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] In the penile vasculature the effects of endothelin-1 seem to be dose-dependent. 2 2 5 Low doses have a vasodilator effect whereas high doses have a vasoconstrictor effect. The vasodilator effect may be mediated by stimulation of endothelial NO production. Endothelin-3 appears to have a predominantly vasodilatator effect on penile vasculature. 2 2 5 Yet at higher doses all three endothelins were shown to elicit cavernosal smooth muscle contraction. 2 2 6 However, endothelin levels in systemic and cavernosal blood did not change from accidity to erection and detumescence in healthy males 2 2 7 or in patients with erectile dysfunction. 2 2 8 In a recently published pilot study of the endothelin-A receptor antagonist BMS-1938, 8 4 this drug caused dosedependent relaxation of cavernosal tissue strips in vitro but failed to improve erectile function in men with mild to moderate erectile dysfunction in vivo. 2 2 6
Endothelium-derived hyperpolarizing factor
There is accumulating evidence for involvement of endothelium-derived hyperpolarizing factors in vasorelaxation. 2 2 9 An endothelium-derived hyperpolarizing factor (EDHF) that promotes endothelium-dependent vasodilation independently of NO and prostacyclin has recently been characterized in wild-type and eNOS knock-out mice. 2 3 0 EDHF-mediated relaxation was found to be sensitive to speci c K + -channel blockade by charybdotoxin and apamin but resistant NOS or PGHS inhibition. This suggests that gap-junctions and Ca 2 + -dependent K + -channels are likely to mediate EDHF-dependent relaxation. Futhermore, the relative contribution of EDHF to relaxation was rather signicant. The nature of EDHF and whether EDHF-like effects in different tissues are mediated by one or by several distinct factors is not yet known. 2 2 9 It has still been suggested that EDHF may provide an alternative or back-up pathway for acetylcholine-mediated vasorelaxation. Finally, acetylcholine-induced endothelium-dependent relaxation, sensitive to blockade of small conductance calcium channels but insensitive to NOS or PGHS blockade, has been identi ed in canine corpus cavernosum as well. 5 3 Again, the clinical signi cance of these observations remains to be established.
Conclusion
Endothelial and erectile dysfunction are both multifactorial but share fundamental risk factors and pathomechanisms. This opens the door for new therapeutic and preventive approaches. Control of cardiovascular risk factors and treatments that restore normal endothelial function in cardiovascular disease are also likely to be bene cial in the prevention and treatment of erectile dysfunction. Future issues to be addressed in erectile dysfunction are the role of endogenous NOS inhibitors, the impact of oxidative stress and the role of EDHF. New arginase inhibitors and speci c Rho-kinase inhibitors may offer additional therapeutic approaches.
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